Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714213 | 1.00 | CTSL (0.37) | CTSLPARP10PARP11PNMTASIC3 | |
| SCHEMBL9148423 | 0.94 | CTSL (0.36) | CTSLPARP10PARP11PNMTASIC3 | |
| SCHEMBL30016658 | 0.88 | CTSL (0.42) | CTSLPARP10PARP11PNMTASIC3 | |
| SCHEMBL3115309 | 0.88 | CTSL (0.42) | CTSLPARP10PARP11PNMTASIC3 | |
| SCHEMBL5440444 | 0.84 | TDP1 (0.37) | CTSLPARP10PARP11PNMTASIC3 | |
| SCHEMBL9144105 | 0.78 | TDP1 (0.36) | CTSLPARP10PARP11PNMTASIC3 | |
| SCHEMBL29414922 | 0.76 | VHL (0.49) | CTSLPNMTMETAP1KDM1ASLC5A2 | |
| SCHEMBL28826798 | 0.76 | KDM1A (0.38) | CTSLPTGS1PTGS2KDM1AHPGD | |
| SCHEMBL9119395 | 0.76 | MAOA (0.43) | HPGDSLC5A2VHLELOCELOB | |
| SCHEMBL11339018 | 0.76 | ALDH1A1 (0.38) | CTSLPARP10PARP11METAP1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-2840076-B1 | BICYCLIC COMPOUND | TOA EIYO LTD (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-9290440-B2 | Bicyclic compound | TOA EIYO LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| US-20150119418-A1 | BICYCLIC COMPOUND | TOA EIYO LTD. (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2840076-A1 | BICYCLIC COMPOUND | TOA Eiyo Ltd. (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-5045551-A | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-09-03 | — | — | US | disclosed |
| US-5023341-A | Acetylene thiochroman | ALLERGAN, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0419130-A2 | Acetylenes disubstituted with a heteroaromatic group and A 2-substituted chromanyl, thiochromanyl or 1,2,3,4- tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0419132-A2 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0419131-A2 | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| US-4980369-A | ANTIARTHRITIC AGENTS, SKIN DISORDERS, ANTIULCER AGENTS, WOUND HEALING AGENTS | ALLERGAN, INC. (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0207605-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | CTSL 3581/4885PARP10 1676/4885PARP11 681/4885 |
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | CTSL 697/4885PARP10 1165/4885PARP11 1591/4885 |
| US-20150119418-A1 | BICYCLIC COMPOUND | C1S, C1R, CYP11B2 | CTSL 2398/4885PARP10 1443/4885PARP11 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.